PharmTech Drug Digest 11.20
News|Articles|December 19, 2013

Encap, Lipocine Partner

Author(s)Melanie Sena

Encap will collaborate with Lipocine to manufacture Lipcine's oral testosterone product, LPCN 1021, for Phase III clinical trials.

Encap Drug Delivery, part of Capsugel’s Dosage Form Solutions business unit, will collaborate with Lipocine, a specialty pharmaceutical company, to manufacture Phase III clinical trial and ICH stability registration batches of Lipocine’s oral testosterone product, LPCN 1021. The product will be manufactured in the company’s high-potency suite at its Livingston, Scotland, R&D site. LPCN 1021 is under development as a testosterone product to treat symptoms related to currently marketed testosterone replacement products. The investigational drug is designed for twice-daily oral dosing.

Encap has completed the transfer of the manufacturing process and validation of all related test methods (in-process and finished product) for LPCN 1021 to its site in Livingston. In addition, Encap has manufactured all the investigational new drug registration batches for the upcoming Phase III clinical supply and stability registration.


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.